Trial Profile

A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGENT-797 (Primary) ; Balstilimab (Primary) ; Botensilimab (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

11 Jul 2025 According to a MiNK Therapeutics media release, the company announced that additional readouts expected in upcoming months.
11 Jul 2025 According to a MiNK Therapeutics media release, the company announced that the separate peer-reviewed case report published in Oncogene.
24 Feb 2025 Results presented in an Agenus media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com